论文部分内容阅读
评价甘露聚糖肽合并化、放疗治疗肿瘤患者的疗效和安全性,同时观察甘露聚糖肽对患者免疫功能的影响。对100例恶性肿瘤患者,随机分为化学治疗组(化疗加甘露聚糖肽)和对照组(化疗)及放射治疗组(放疗加甘露聚糖肽)和对照组(放疗),分别对患者的治疗有效率、外周血CD3+、CD4+、CD8+、CD4+/CD8+、淋巴细胞转化率(LTT)、外周血白细胞(WBC)、放/化疗不良反应等指标进行比较。结果:(1)近期疗效:化疗、放疗治疗组有效率分别为68%,60%,对照组有效率分别为40%,32%,治疗组和对照组有效率差异有显著性(P<0.01)。(2)与对照组相比,化疗、放疗治疗组T细胞亚群CD3+、CD4+、CD4+/CD8+及LTT均明显升高,CD8+降低,其中化学治疗组与对照组相比CD3+、CD4+升高更明显,差异有显著性(P<0.01),放射治疗组与对照组相比CD8+略有降低,差异无显著性(P>0.05)。其余各项检测指标,治疗组与对照组相比,均存在明显的差异(P<0.05)。(3)外周血常规:治疗组外周血WBC下降病例均少于对照组,且WBC下降程度较轻,化疗、放疗治疗组与相应对照组比较差异有显著性(P<0.05)。(4)不良反应:与对照组相比,化疗、放疗治疗组发生恶心,呕吐、体重下降的病例减少,发热病例增多。甘露聚糖肽合并化、放疗可以提高恶性肿瘤的临床疗效,并提高患者的免疫功能。
To evaluate the efficacy and safety of mannan peptide in combination with radiotherapy for the treatment of cancer patients, and to observe the effect of mannan peptide on immune function in patients. 100 patients with malignant tumor were randomly divided into chemotherapy group (chemotherapy plus mannan peptide) and control group (chemotherapy) and radiotherapy group (radiotherapy plus mannan peptide) and control group (radiotherapy), respectively, patients Treatment efficiency, peripheral blood CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, lymphocyte transformation rate (LTT), peripheral blood leukocytes (WBC), radiotherapy / chemotherapy adverse reactions and other indicators were compared. Results: (1) The short-term curative effect: The effective rates of the chemotherapy and radiotherapy groups were 68% and 60%, respectively. The effective rates of the control group were 40% and 32% respectively. There was significant difference between the treatment group and the control group ). (2) Compared with the control group, the levels of CD3 +, CD4 +, CD4 + / CD8 + and LTT in the T cell subsets and the CD8 + in the chemotherapy and radiotherapy groups were significantly higher than those in the control group Significantly, the difference was significant (P <0.01). There was no significant difference in CD8 + between radiotherapy group and control group (P> 0.05). The rest of the test indicators, the treatment group compared with the control group, there were significant differences (P <0.05). (3) Peripheral blood routine: WBC decreased in the treatment group was less than that in the control group, and WBC decreased less. There was significant difference between the chemotherapy and radiotherapy groups and the corresponding control group (P <0.05). (4) adverse reactions: compared with the control group, chemotherapy, radiotherapy treatment group nausea, vomiting, weight loss decreased cases, increased fever cases. Mannan peptide merger, radiotherapy can improve the clinical efficacy of malignant tumors, and improve the patient’s immune function.